EXLS · ExlService Holdings, Inc.

Current Thesis

ExlService Holdings’ AI-services re-rating requires renewed revenue confirmation: a daily close above the August reference close of $37.53, accompanied by organic growth guidance of at least 13%, would validate the recovery case; a daily close below $34 would invalidate it. The operating evidence remains the 2026-07-28 results: second-quarter revenue of $594.8 million and data-and-AI-led revenue of $362.6 million, according to the earnings release and quarterly filing. The latest market evidence is weaker: the supplied adjusted daily close was $35.15 on 2026-09-18.

Since the September 5 assessment, EXL appeared at the 2026-09-08 Citi Global TMT Conference and launched its new brand on 2026-09-09. The brand announcement reiterated that more than 60% of revenue was data-and-AI-led but supplied no new quarterly results or financial guidance. These are visibility events rather than fresh financial confirmation. EXL events; September 9 announcement.

The lifecycle assessment is an inference: the narrative is maturing — the September 8 conference and September 9 brand launch repeated the established AI-services message, while the September 18 close remained below the August 21 reference close of $37.53. The case retains low conviction because the latest price observation provides no recovery confirmation before the leadership transition and estimated October results date.

Bullish and bearish views on ExlService Holdings, Inc.

The model's bull view on ExlService Holdings, Inc. (EXLS), in brief: Revenue supports the AI-services thesis. The bear view: Profit growth trails revenue growth. The second-quarter 2026 Form 10-Q reported net income under generally accepted accounting principles of $64.5 million versus $66.1 million a year earlier, despite the reported revenue increase. Higher adjusted earnings per share therefore do… Both cases follow in full.

Bull Case

• Revenue supports the AI-services thesis. The 2026-07-28 earnings release reported second-quarter revenue of $594.8 million, up 15.6% year over year, and adjusted diluted earnings per share of $0.59 versus $0.49 a year earlier. Those measured results support the operating premise that AI deployment can generate services revenue.
• Organic guidance supplies a test. On the 2026-07-29 earnings call, management guided to 13–14% organic constant-currency growth for 2026 and separately disclosed an expected $28–32 million revenue contribution from iMerit. Maintaining that organic range at the next results release would support the thesis; guidance below 13% would contradict it.
• The revenue mix has shifted. The second-quarter 2026 Form 10-Q reported data-and-AI-led revenue of $362.6 million versus $278.8 million a year earlier. This is measured segment growth; the filing does not establish how much represents incremental AI spending versus services classified within the broader category.

Bear Case

• Profit growth trails revenue growth. The second-quarter 2026 Form 10-Q reported net income under generally accepted accounting principles of $64.5 million versus $66.1 million a year earlier, despite the reported revenue increase. Higher adjusted earnings per share therefore do not establish growth in reported net income.
• Legacy services remain a drag. The same quarterly filing reported digital-operations revenue of $232.2 million versus $235.7 million a year earlier. A further decline alongside slowing data-and-AI-led revenue growth at the next report would weaken the argument that the mix shift offsets pressure on the legacy business.
• Leadership continuity remains unresolved. EXL’s 2026-09-02 announcement said Vivek Jetley, head of Insurance, Healthcare and Life Sciences, would depart effective 2026-10-26; that announcement named no successor. Insurance generated $197.8 million in second-quarter 2026 revenue, according to the quarterly filing, making the transition relevant to a substantial revenue line.

Setup & Price Structure

The supplied adjusted price series records a $35.15 daily close on 2026-09-18, a three-month price increase of 37.3%, and a 14-period relative strength index (RSI) of 29.0. The same snapshot places the shares 20.2% below their $44.03 trailing-year high. These observations describe a longer-period recovery accompanied by weak recent momentum; RSI alone does not establish a reversal.

The existing research threshold remains a daily close below $34, beneath the August shelf identified by the $34.89 close on 2026-08-07 and $34.90 close on 2026-08-11. The recovery reference remains the $37.53 close on 2026-08-21. A subsequent daily close above $37.53 would provide price confirmation; September 18’s close does not.

Analyst enthusiasm is observable, but positioning is not established. As accessed on 2026-09-19, Benzinga listed nine positive ratings, while MarketBeat listed six positive ratings and one neutral rating. Both recorded TD Cowen’s 2026-08-27 target increase to $45; their different coverage universes prevent treating the counts as interchangeable. These observations cannot establish crowded ownership or expanding retail participation. Benzinga ratings; MarketBeat ratings.

Catalyst Calendar (next 30 days)

For 2026-09-19 through 2026-10-19, no company-confirmed upcoming event was listed on EXL’s events page when checked on September 19. An earnings-scheduling announcement has no verified date and is therefore not assigned a speculative calendar entry. EXL events.

• 2026-10-26 — Leadership transition becomes effective. The departure date comes from EXL’s 2026-09-02 announcement. A named successor by that date would resolve the succession question; the date passing without one would leave it open.
• ~2026-10-27, estimated — Third-quarter results. Yahoo Finance lists October 27, but EXL’s calendar does not confirm it as of 2026-09-19. This later event is the operating test of the thesis: whether management maintains its 13–14% organic constant-currency growth outlook and reports continued data-and-AI-led revenue growth. Third-party earnings estimate; EXL calendar.

What Would Change Our Mind

Loss of the August support structure ends the published recovery case: a daily close below $34 is the price invalidation, beneath the August 7 and August 11 shelf closes. Separately, management reducing its 2026 organic constant-currency growth outlook below 13% at the next results release would break the operating premise established on the July 29 call.

The positive resolution requires both market and operating confirmation: a daily close above the August 21 reference close of $37.53 and organic constant-currency growth guidance of at least 13% at the next results release. A brand announcement or analyst target increase alone does not satisfy those conditions.

Correlation Notes

This remains a single-name assessment. Second-quarter 2026 data-and-AI-led revenue of $362.6 million and insurance revenue of $197.8 million identify business exposures, but they do not measure share-price correlation with AI software or managed-care companies. No matched peer-return sample supports a group-momentum claim, and the research therefore assigns no confirming role to a presumed sector bid.